ELLIPTA Versus DISKUS plus HandiHaler in COPD: A Randomized, Open-Label, Crossover Study in a Clinical Trial Setting

Area of Science:

• Pulmonary Medicine
• Pharmacology
• Medical Device Technology

Background:

• Inhaler misuse in chronic obstructive pulmonary disease (COPD) management significantly impacts treatment effectiveness.
• Accurate inhaler technique is crucial for optimal drug delivery and patient outcomes in COPD.

Purpose of the Study:

• To compare the correct usage rates and critical error rates between the ELLIPTA and DISKUS plus HandiHaler inhaler devices in patients with COPD.
• To assess patient preference for the ELLIPTA versus DISKUS plus HandiHaler devices.

Main Methods:

• A randomized, open-label, crossover study involving 217 COPD patients.
• Participants were assessed on correct inhaler use at baseline, 28 days, and 56 days.
• Correct inhaler use was defined as zero critical errors after 28 days of use.

Main Results:

• A significantly higher proportion of participants correctly used ELLIPTA (96%) compared to DISKUS plus HandiHaler (87%) after 28 days (p < 0.001).
• The odds of correct use were 6.88 times greater with ELLIPTA.
• Critical error rates were substantially lower with ELLIPTA (>99% vs. 89%).

Conclusions:

• ELLIPTA demonstrates superior correct use rates and lower critical error rates compared to DISKUS plus HandiHaler for COPD maintenance therapy.
• ELLIPTA was the preferred inhaler device among study participants.